

Tirandamycins from *Streptomyces* sp. 17944 Inhibiting the Parasite *Brugia malayi* Asparagine tRNA Synthetase


Zhiguo Yu,^{†,‡} Sanja Vodanovic-Jankovic,[#] Nathan Ledebner,[‡] Sheng-Xiong Huang,^{†,‡} Scott R. Rajski,[‡] Michael Kron,^{*,#} and Ben Shen^{*,†,§,||,‡}

Department of Chemistry, Department of Molecular Therapeutics, and Natural Products Library Initiative at TSRI, Scripps Florida, Jupiter, Florida 33458, United States, Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin–Madison, Madison, Wisconsin 53705, United States, and Department of Pathology and Biotechnology and Bioengineering Center, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States

mkron@mcw.edu; shenb@scripps.edu

Received February 15, 2011

ABSTRACT



Lymphatic filariasis is caused by the parasitic nematodes *Brugia malayi* and *Wuchereria bancrofti*, and asparaginyl-tRNA synthetase (AsnRS) is considered an excellent antifilarial target. The discovery of three new tirandamycins (TAMs), TAM E (1), F (2), and G (3), along with TAM A (4) and B (5), from *Streptomyces* sp. 17944 was reported. Remarkably, 5 selectively inhibits the *B. malayi* AsnRS and efficiently kills the adult *B. malayi* parasite, representing a new lead scaffold to discover and develop antifilarial drugs.

Lymphatic filariasis (LF), also known as elephantiasis, is caused by the parasitic nematodes *Brugia malayi* and *Wuchereria bancrofti* and represents a worldwide health crisis with over 200 million people infected and another 20% of the global population at risk for infection.^{1,2} In 1997, the World Health Organization (WHO) passed a resolution, prioritizing “the elimination of LF as a public health problem” and more recently announced the discovery of effective macrofilaricides, drugs that can kill adult

female worms, a top priority.³ This action was spurred by concerns related to resistance to current antihelminth agents in addition to the long-standing desire to impair transmission among hosts. Programs aimed at interrupting disease transmission have been based on mass distribution of ivermectin and albendazole.^{3–6} However, resistance to both agents is well-known and both agents suffer from serious limitations: neither agent is effective at killing adult worms (macrofilariae) and serious side effects are associated with both drugs.^{7–9} A clear need exists to identify new antiparasitic agents with new, alternative modes of action.⁹

[†] Department of Chemistry, Scripps Florida.

[§] Department of Molecular Therapeutics, Scripps Florida.

^{||} Natural Products Library Initiative at TSRI, Scripps Florida.

[‡] University of Wisconsin–Madison.

[‡] Department of Pathology, Medical College of Wisconsin.

[#] Biotechnology and Bioengineering Center, Medical College of Wisconsin.

(1) WHO: *Lymphatic Filariasis: Reasons for Hope*; Dzenowagis, J., Ed.; World Health Organization: Geneva, 1997.

(2) Kron, M.; Marquard, K.; Hartlein, M.; Price, S.; Lederman, R. *FEBS Lett.* **1995**, *374*, 122–124.

(3) Ridley, R. G.; Kita, K. *Expert Opin. Drug Discovery* **2007**, *2* (Suppl. 1), S1.

(4) Woods, D. J.; Lauret, C.; Geary, T. G. *Expert Opin. Drug Discovery* **2007**, *2*, S25–S33.

(5) Geary, T. G. *Trends Parasitol.* **2005**, *21*, 530–532.

(6) Molyneux, D. H.; Bradley, M.; Hoerauf, A.; Kyelem, D.; Taylor, M. J. *Trends Parasitol.* **2003**, *19*, 516–522.

(7) Prichard, R. K. *Expert Opin. Drug Discovery* **2007**, *2*, S41–S52.

(8) Fox, L. M.; Furness, B. W.; Haser, J. K.; Desire, D.; Brissau, J.-M.; Milord, M.-D.; Lafontant, J.; Lammie, P. J.; Beach, M. J. *Am. J. Trop. Med. Hyg.* **2005**, *73*, 115–121.

Aminoacyl tRNA synthetases (AARSSs) were the first filarial targets embraced by the WHO¹⁰ and are generally regarded as excellent therapeutic targets because they (i) perform important primary and secondary transformations within eukaryotes including filarial and other human and veterinary parasites, (ii) are essential to microbial viability, and (iii) demonstrate primary and secondary structural heterogeneity while sharing a common catalytic site topology critical to recognition by inhibitors that block the synthesis or release of the aminoacyl adenylate intermediate.

Among the AARSSs, asparaginyl-tRNA synthetase (AsnRS) is, in particular, an excellent filarial target because (i) it is expressed in both sexes, adults, and larvae of *B. malayi*;^{2,11} (ii) it is well-characterized biochemically and structurally in several species, including *B. malayi*; and (iii) a high-throughput screening (HTS) platform with recombinant *B. malayi* AsnRS for inhibitors has been developed.¹² Most recently, the complete atomic structure of the *B. malayi* AsnRS has been determined and the structural basis of asparagine and false substrate recognition elucidated.¹³

Despite the rise to prominence of combinatorial chemistry, natural products remain a valuable source of new drug leads and have demonstrated almost limitless potential in showcasing new molecular scaffolds with clinically relevant biological activities.¹⁴ As part of a drug discovery program targeting the *B. malayi* AsnRS, we recently completed an HTS campaign of ~73 000 microextracts, from a collection of 36 720 microbial strains, for activity against recombinant *B. malayi* AsnRS. Of the extracts screened, 199, representing 177 strains, induced at least 70% inhibition. We now report bioassay-guided dereplication of one of these active strains, *Streptomyces* sp. 17944, discovering three new tirandamycins (TAMs), TAM E (1), F (2), and G (3) along with two known TAMs, TAM A (4) and TAM B (5) (Figure 1A). Remarkably, 5 selectively inhibits the *B. malayi* AsnRS and efficiently kills the adult *B. malayi* parasite. To our knowledge TAMs have not been recognized previously for use in the treatment or prevention of LF. Consequently, 5 represents a new lead scaffold for the discovery and development of antifilarial drugs.

The *S. sp.* 17944 strain was cultivated in the ISP2 medium, and natural product isolation was guided by bioassay for inhibitory activity against recombinant *B. malayi* AsnRS (see Supporting Information). Thus, a solid phase extract of 7.2 L of the resultant fermentation, prepared using 3% Amberlite XAD-16 resin and




Figure 1. Isolation and structural determination of TAMs from *S. sp.* 17944: (A) structures of the three new TAMs, TAM E (1), F (2), and G (3), and the two known TAMs, TAM A (4) and B (5); (B) key COSY and HMBC correlations for 1–3; and (C) key NOESY correlations for 1 and 3.

previously described procedures,¹⁵ was subjected to silica gel and Sephadex LH-20 chromatography, followed by further purification with reversed-phase HPLC, to afford 1–5 (see Supporting Information). Analysis of high resolution ESI-MS (HRESIMS) data and ¹H and ¹³C NMR spectra (Table S1) suggested 4 and 5 to be TAM A and B, respectively, whose identities were unambiguously confirmed by extensive 1D and 2D NMR (gCOSY, gHSQC, and gHMBC) analyses, as well as comparison to previously reported spectroscopic data (Figure 1A).¹⁶

The molecular formula of 1 was determined to be C₂₂H₂₉NO₇ by HRESIMS, affording an [M + Na]⁺ ion at *m/z* 442.18355 (calculated [M + Na]⁺ ion at *m/z* 442.18362) and indicating that 1 differs from 4 (C₂₂H₂₇NO₇) by the presence of two additional protons. The ¹H and ¹³C NMR spectral data (Tables 1 and S1) supported a close structural relationship between 1 and 4, demonstrated by the consistent appearance of the olefinic and methyl signals of the dienoyl acyl chain and the geminal protons of the tetramic acid methylene carbon. Correlations observed in gDQCOSY, gHSQC, and gHMBC experiments further confirmed 4 and 1 have identical carbon backbones except for the oxygenation patterns of the bicyclic ketal moiety. Close examination of the NMR data for 1 and 4 (Tables 1 and S1) revealed that the disappearance of the C-10 carbonyl carbon of 4

(9) (a) Kron, M. A.; Kuhn, L. A.; Sanschagrin, P. C.; Hartlein, M.; Grotli, M.; Cusack, S. *J. Parasitol.* **2003**, *89*, S226–S235. (b) Hoerauf, A. *Curr. Opin. Infect. Disease* **2008**, *21*, 673–681. (c) Bockarie, M. J.; Deb, R. M. *Curr. Opin. Infect. Disease* **2010**, *23*, 617–620.

(10) Kron, M. A.; Ramirez, B. L.; Ramirez, Y. *Expert Opin. Drug Discovery* **2007**, *2*, S1–S8.

(11) Nilsen, T. W.; Maroney, P. A.; Goodwin, R. G.; Perrine, K. G.; Denkar, J. A.; Nanduri, J.; Kazura, J. *Proc. Natl. Acad. Sci. U.S.A.* **1988**, *85*, 3604–3607.

(12) Danel, F.; Caspers, P.; Nuoffer, C.; Hartlein, M.; Kron, M. A.; Page, M. G. *Curr. Drug Discovery Technol.* **2010**, *8*, 66–75.

(13) Crepin, T.; Peterson, F.; Hartlein, M.; Jensen, D.; Wang, C.; Cusack, S.; Kron, M. *J. Mol. Biol.* **2011**, *405*, 1056–1069.

(14) Newman, D. J.; Cragg, G. M. *J. Nat. Prod.* **2007**, *70*, 461–477.

(15) Ju, J.; Seo, J.-W.; Her, Y.; Lim, S.-K.; Shen, B. *Org. Lett.* **2007**, *9*, 5183–5186.

(16) (a) Meyer, C. E. *J. Antibiot.* **1971**, *24*, 558–560. (b) Carlson, J. C.; Li, S.; Burr, D. A.; Sherman, D. H. *J. Nat. Prod.* **2009**, *72*, 2076–2079.

Table 1. Summary of ^1H (500 MHz) and ^{13}C (125 MHz) Spectroscopic Data for **1**, **2**, and **3** (in CDCl_3)

position	1 (J in Hz)		2 (J in Hz)		3 (J in Hz)	
	δ_{H} mult	δ_{C}	δ_{H} mult	δ_{C}	δ_{H} mult	δ_{C}
1		175.7, s		175.7, s		175.5, s
2	7.15, d (16.0)	116.5, d	7.16, d (15.5)	116.6, d	7.14, d (16.0)	116.1, d
3	7.60, d (15.5)	150.6, d	7.58, d (16.0)	150.5, d	7.59, d (15.5)	150.5, d
4		134.7, s		135.3, s		134.4, s
5	6.29, d (9.5)	145.4, d	6.07, d (9.5)	147.0, d	6.24, d (9.5)	146.0, d
6	2.89, m	35.0, d	2.64, m	39.2, d	2.87, m	34.3, d
7	3.92, d (10.5)	76.2, d	3.93, m	71.1, d	3.58, d (11.0)	79.2, d
8	2.04, m	36.6, d	1.90, m	26.1, t	1.98, m	35.3, d
			1.66, m			
9	3.98, m	71.8, d	4.15, m	68.3, d	4.01, m	73.2, d
10	4.41, d (7.0)	67.3, d	4.30, d (6.5)	63.7, d	3.96, m	77.1, d
11	3.19, s	64.2, d	3.15, s	63.9, d	3.95, m	75.8, d
12		56.4, s		56.3, s	1.78, m	47.1, d
13		96.5, s		96.4, s		99.3, s
14	1.42, s	22.3, q	1.37, s	22.5, q	1.36, s	26.9, q
15	1.93, s	12.5, q	1.92, s	12.9, q	1.91, s	12.3, q
16	1.14, d (7.0)	17.3, q	1.08, d (7.0)	16.3, q	1.13, d (6.0)	17.1, q
17	0.96, d (7.5)	13.2, q	—	—	0.96, d (7.5)	12.8, q
18	1.40, s	16.6, q	1.35, s	16.7, q	1.14, d (6.5)	12.8, q
2'		176.7, s		176.8, s		176.5, s
3'		100.1, s		100.2, s		99.8, s
4'		192.8, s		192.8, s		192.4, s
5'	3.82, s	51.8, t	3.82, s	51.8, t	3.82, s	51.5, t

(δ_{C} 202.8) with the concomitant appearance of the oxygenated methine carbon (δ_{C} 67.3, C-10) and an additional proton signal (δ_{H} 4.41, H-10), together with the MS data, suggests that **4** was likely a C-10 reduced congener of **1** (Figure 1A). This conclusion was further confirmed by gHMBC correlations of H-10 (δ_{H} 4.41) with C-8 (δ_{C} 36.6), C-9 (δ_{C} 71.8), C-11 (δ_{C} 64.2), and C-12 (δ_{C} 56.4) and the COSY correlation between H-10 and H-9 (Figure 1B). Since the absolute stereochemistry of **4** was known,¹⁷ **1**, with the exception of C-10, was assigned the same stereochemistry as that of **4** on the basis of its biosynthetic origin. Finally, the C-10 stereochemistry of **1** was deduced on the basis of the NOESY spectrum. Key correlations between H-10/H-9, H-11/H-18, and H-9/H-8 (Figure 1C) are consistent with the assignment of an *R* configuration to C-10 of **1**, which we named TAM E (Figure 1A).

The molecular formula of **2** was determined to be $\text{C}_{21}\text{H}_{27}\text{NO}_7$ by HRESIMS, yielding an $[\text{M} + \text{Na}]^+$ ion at m/z 428.16998 (calculated $[\text{M} + \text{Na}]^+$ ion at m/z 428.16797), which differs from **1** by the absence of a CH_2 unit. The structure of **2** was established by careful comparison of the NMR data between **1** and **2** (Table 1). The absence of a doublet methyl signal and a methine signal with the concomitant presence of one new methylene signal suggested **2** as a desmethyl congener of **1**. This conclusion was further supported by a gHMBC correlation of H_a -8 (δ_{H} 1.66) with C-6 (δ_{C} 39.2), C-7 (δ_{C} 71.1), and C-10 (δ_{C} 63.7) and COSY correlations among H_a -8 (δ_{H} 1.66), H-7 (δ_{H} 3.93), and H-9 (δ_{H} 4.15) (Figure 1B). Thus, **2** was

finally assigned as 8-desmethyl TAM E, hereafter regarded as TAM F, with the same absolute stereochemistry as that of **1** on the basis of their common biosynthetic origin (Figure 1A).

The molecular formula of **3** was determined to be $\text{C}_{22}\text{H}_{31}\text{NO}_7$ by HRESIMS, giving rise to an $[\text{M} + \text{Na}]^+$ ion at m/z 444.19900 (calculated $[\text{M} + \text{Na}]^+$ ion at m/z 444.19927), which differs from **1** by the presence of two additional protons. Careful analysis of the ^1H and ^{13}C NMR data for **1** and **3** indicated that the characteristic 11, 12-epoxide resonances in **1** (δ_{C} 64.2 for C-11 and δ_{C} 56.4 for C-12) were replaced by a downfield shifted oxygenated methine signal (δ_{C} 75.8 for C-11) and an upfield shifted methine signal (δ_{C} 47.1 for C-12) in **3** (Table 1). Together with the MS data, **3** was suggested to be the epoxide ring-reduced congener of **1**, which was further supported by gHMBC correlations of H-11 (δ_{H} 3.95) with C-9 (δ_{C} 73.2) and H-12 (δ_{H} 1.78) with C-10 (δ_{C} 77.1) and C-13 (δ_{C} 99.3), as well as COSY correlations among H-12 (δ_{H} 1.78), H-11 (δ_{H} 3.95), and H-18 (δ_{H} 1.14) (Figure 1B). The stereochemistry of **3** was assigned as 10*R*, 11*R*, and 12*R* on the basis of a NOESY experiment, and key observations included correlations between H-10/H-7, H-12/H-18, and H-12/H-14 (Figure 1C). Finally, **3** was named TAM G, with the rest of its stereochemistry to be the same as that of **4** on the basis of their common biosynthetic origin (Figure 1A).

Having each of the TAMs purified and their structures established, we re-evaluated their inhibitory activity against the *B. malayi* AsnRS, taking advantage of our recently reported nonradioactive assay that uses malachite green to measure rates and yields of phosphate generated

(17) Duchamp, D. J.; Branfman, A. R.; Button, A. C.; Rinehart, K. L. *J. Am. Chem. Soc.* **1973**, *95*, 4077–4078.

by the recombinant AsnRS.¹² This “pretransfer editing assay” exploits the novel asparagine substrate mimic L-aspartate β -hydroxamate to drive the enzymatic activity of AsnRS. A molecular explanation for why this asparagine mimic functions so efficiently in the assay has been provided by our recently solved *B. malayi* AsnRS structure.¹³ Assays of pure **1–5** revealed that **5** inhibited *B. malayi* AsnRS with an IC₅₀ of 30 μ M; the other four TAMs showed IC₅₀ > 200 μ M. Remarkably, under identical assay conditions, **5** exhibited minimally 10-fold selectivity for the *B. malayi* AsnRS over the human AsnRS (Figure 2A), suggesting **5** as a promising lead for antifilarial drug discovery.




Figure 2. Summary of antifilarial activity of **5**. (A) *In vitro* analysis of AsnRS inhibition by **5** against human and filarial AsnRS using pretransfer editing assay. Lane/Reaction contents: (1) human AsnRS; (2) human AsnRS, 150 μ M **5**; (3) *B. malayi* AsnRS; (4) *B. malayi* AsnRS, 150 μ M **5**. Assays employed limiting (50%) maximal enzyme activity. (B) Live worms are coiled and motile, whereas dead worms (C) are elongated and nonmotile. (D) Live worms reduce MTT which leads to absorption at 510 nm. Lane/Reaction contents: (1) *B. malayi*, DMSO; (2) *B. malayi*, 100 μ M albendazole as a positive control; (3) *B. malayi*, 100 μ M **5**.

Finally, we showed that **5** can efficiently kill the adult *B. malayi* worm *in vitro*. Live adult female *B. malayi* worms were maintained in 6-well plates, and **5** (100 μ M) was added to select wells compared with albendazole, a known

(18) Comley, J. C. W.; Rees, M. J.; Turner, C. H.; Jenkins, D. C. *Int. J. Parasitol.* **1989**, *19*, 77–83.

LF drug, serving as a positive control.^{8,9} *B. malayi* are very amenable to visual health assessment as healthy worms are vigorously motile and coiled, whereas dead worms assume an elongated morphology devoid of movement (Figures 2B and 2C). Worm death can also be differentiated from simple paralysis, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2*H*-tetrazolium bromide (MTT); live worms reduce MTT to formazan, a spectroscopically unique species whose absorption at 510 nm provides a real-time measurement of filarial viability.¹⁸ As shown in Figure 2D, **5** kills the adult worms with a yield similar to that observed with albendazole. The efficiency with which **5** (100 μ M) kills adult worms is remarkable: whereas 100 μ M albendazole requires >10 days to effectively kill worms, **5** induces dramatic filarial death after less than 24 h. The IC₅₀ for **5** to kill the adult worms calculated using the MTT assay was found to be 1 μ M. This finding, in combination with the ability of **5** to selectively inhibit the filarial AsnRS, thereby targeting *B. malayi*, constitutes the basis for continued chemical and biological efforts to understand the mode of action of **5** and the application of both combinatorial biosynthesis and medicinal chemistry methods to the **5** scaffold for a structure–activity relationship study. The fact that the TAM biosynthetic gene cluster has been recently cloned and partially characterized¹⁹ further heightens enthusiasm for the application of combinatorial biosynthesis strategies to over-produce **5** and to enhance structural diversity. Although other activities²⁰ known for the TAMs may complicate future drug development effort, **5** represents an outstanding natural product lead scaffold that could be exploited to combat the global health crisis of LF.

Acknowledgment. We thank the Filariasis Research Reagent Resource, Division of Microbiology and Infectious Diseases, NIAID, NIH for providing adult *B. malayi* and the Analytical Instrumentation Center of the School of Pharmacy, UW-Madison for support in obtaining MS and NMR data. This work was supported in part by NIH Grants U01 A1053877 (M.K.) and GM086184 (B.S.).

Supporting Information Available. Experimental procedures, MS and ¹H and ¹³C NMR data of **1–5**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

(19) Carlson, J. C.; Fortman, J. L.; Anzai, Y.; Li, S.; Burr, D. A.; Sherman, D. H. *ChemBioChem*. **2010**, *11*, 564–572.

(20) (a) Reusser, F. *Infect. Immun.* **1970**, *2*, 82–88. (b) Reusser, F. *Antimicrob. Agents Chemoth.* **1976**, *10*, 618–622.